ASX:RGS

Regeneus (RGS) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
13,076 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
RGS stock logo

About Regeneus Stock (ASX:RGS)

Regeneus Ltd, a clinical stage regenerative medicine company, develops cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, neuropathic pain, and dermatology diseases in Australia. The company's platform technology includes Progenza, a multi-synergistic therapy, which has completed Phase I clinical trial for the treatment of osteoarthritis; and in pre-clinical stage to treat neuropathic pain. It also develops Sygenus that is in pre-clinical stage for the treatment of skin wound healing. The company was incorporated in 2007 and is headquartered in Paddington, Australia.

RGS Stock News Headlines

READ THIS – If You Missed Out On The AI Boom
Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”
Russell 1000 RGS Retail (^R1RGSRET)
Closing Bell: When doves fly, markets soar
Regis Corp RGS
READ THIS – If You Missed Out On The AI Boom
Adam’s research shows a radical new technology is set to grow 10X faster than the internet … and drastically alter manufacturing, healthcare, agriculture … even energy. Nvidia’s CEO said it will be, “flat out, the biggest [tech] revolution ever.”
Regeneus Ltd
Regis (NYSE: RGS)
Ocugen: Still Struggling
Regis Corporation (RGS)
Regeneus Ltd (RGS.AX)
See More Headlines
Receive RGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Regeneus and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
9,000
Year Founded
N/A

Profitability

Net Income
$-1,690,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.02 million

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
-0.24
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Karolis Rosickas
    Chief Executive Officer
  • Prof. Graham Vesey Ph.D. (Age 59)
    Chief Scientific Officer & Executive Director
    Comp: $39.28k
  • Dr. Charlotte Morgan Ph.D.
    Head of Research & Development
  • Ling Leung Hang
    Company Secretary

This page (ASX:RGS) was last updated on 5/2/2024 by MarketBeat.com Staff

From Our Partners